Skip to main content
Top
Published in: European Radiology 11/2019

Open Access 01-11-2019 | Breast Cancer | Breast

Evaluation of single-view contrast-enhanced mammography as novel reading strategy: a non-inferiority feasibility study

Authors: M. B. I. Lobbes, J. Hecker, I. P. L. Houben, R. Pluymakers, C. Jeukens, U. C. Laji, S. Gommers, J. E. Wildberger, P. J. Nelemans

Published in: European Radiology | Issue 11/2019

Login to get access

Abstract

Background

Guidelines recommend screening of high-risk women using breast magnetic resonance imaging (MRI). Contrast-enhanced mammography (CEM) has matured, providing excellent diagnostic accuracy. To lower total radiation dose, evaluation of single-view (1 V) CEM exams might be considered instead of double-view (2 V) readings as an alternative reading strategy in women who cannot undergo MRI.

Methods

This retrospective non-inferiority feasibility study evaluates whether the use of 1 V results in an acceptable sensitivity for detecting breast cancer (non-inferiority margin, − 10%). CEM images from May 2013 to December 2017 were included. 1 V readings were performed by consensus opinion of three radiologists, followed by 2 V readings being performed after 6 weeks. Cases were considered “malignant” if the final BI-RADS score was ≥ 4, enabling calculation of sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). Histopathological results or follow-up served as a gold standard.

Results

A total of 368 cases were evaluated. Mean follow-up for benign or negative cases was 20.9 months. Sensitivity decreased by 9.6% from 92.9 to 83.3% when only 1 V was used for evaluation (p < 0.001). The lower limit of the 90% confidence interval around the difference in sensitivity between 1 V and 2 V readings was − 15% and lies below the predefined non-inferiority margin of − 10%. Hence, non-inferiority of 1 V to 2 V reading cannot be concluded. AUC for 1 V was significantly lower, 0.861 versus 0.899 for 2 V (p = 0.0174).

Conclusion

Non-inferiority of 1 V evaluations as an alternative reading strategy to standard 2 V evaluations could not be concluded. 1 V evaluations had lower diagnostic performance compared with 2 V evaluations.

Key Points

• To lower radiation exposure used in contrast-enhanced mammography, we studied a hypothetical alternative strategy: single-view readings (1 V) versus (standard) double-view readings (2 V).
• Based on our predefined margin of − 10%, non-inferiority of 1 V could not be concluded.
• 1 V evaluation is not recommended as an alternative reading strategy to lower CEM-related radiation exposure.
Literature
1.
go back to reference Phi XA, Saadatmand S, De Bock GH et al (2016) Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. Br J Cancer 6:631–637CrossRef Phi XA, Saadatmand S, De Bock GH et al (2016) Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. Br J Cancer 6:631–637CrossRef
2.
go back to reference Saadatmand S, Obdeijn IM, Rutgers EJ et al (2015) Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). Int J Cancer 137:1729–1738CrossRef Saadatmand S, Obdeijn IM, Rutgers EJ et al (2015) Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). Int J Cancer 137:1729–1738CrossRef
3.
go back to reference Phi XA, Houssami N, Obdeijn IM et al (2015) Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence form an individual patient data meta-analysis. J Clin Oncol 33:349–356CrossRef Phi XA, Houssami N, Obdeijn IM et al (2015) Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence form an individual patient data meta-analysis. J Clin Oncol 33:349–356CrossRef
4.
go back to reference Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89CrossRef Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89CrossRef
5.
go back to reference Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296–1316CrossRef Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296–1316CrossRef
6.
go back to reference Mann RM, Balleyguier C, Baltzer PA et al (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25:3669–3678CrossRef Mann RM, Balleyguier C, Baltzer PA et al (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25:3669–3678CrossRef
7.
go back to reference Zhang Y, Ren H (2017) Meta-analysis of diagnostic accuracy of magnetic resonance imaging and mammography for breast cancer. J Cancer Res Ther 13:862–868CrossRef Zhang Y, Ren H (2017) Meta-analysis of diagnostic accuracy of magnetic resonance imaging and mammography for breast cancer. J Cancer Res Ther 13:862–868CrossRef
8.
go back to reference Gulani V, Calamante F, Shellock FG et al (2017) Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 16:564–570CrossRef Gulani V, Calamante F, Shellock FG et al (2017) Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 16:564–570CrossRef
9.
go back to reference Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17:1359–1370CrossRef Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17:1359–1370CrossRef
10.
go back to reference Lobbes MB, Smidt ML, Houwers J, Tjan-Heijnen VC, Wildberger JE (2013) Contrast enhanced mammography: techniques, current results, and potential indications. Clin Radiol 68:935–944CrossRef Lobbes MB, Smidt ML, Houwers J, Tjan-Heijnen VC, Wildberger JE (2013) Contrast enhanced mammography: techniques, current results, and potential indications. Clin Radiol 68:935–944CrossRef
11.
go back to reference Jochelson MS, Dershaw DD, Sung JS et al (2013) Bilateral contrast-enhanced dual-energy mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology 266:743–751CrossRef Jochelson MS, Dershaw DD, Sung JS et al (2013) Bilateral contrast-enhanced dual-energy mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology 266:743–751CrossRef
12.
go back to reference Fallenberg EM, Schmitzberger FF, Amer H et al (2017) Contrast-enhanced spectral mammography vs. mammography and MRI: clinical performance in a multi-reader evaluation. Eur Radiol 27:2752–2764 Fallenberg EM, Schmitzberger FF, Amer H et al (2017) Contrast-enhanced spectral mammography vs. mammography and MRI: clinical performance in a multi-reader evaluation. Eur Radiol 27:2752–2764
13.
go back to reference Li L, Roth R, Germaine P et al (2017) Contrast-enhanced spectral mammography (CESM) versus breast magnetic resonance imaging (MRI): a retrospective comparison in 66 breast lesions. Diagn Interv Imaging 98:113–123CrossRef Li L, Roth R, Germaine P et al (2017) Contrast-enhanced spectral mammography (CESM) versus breast magnetic resonance imaging (MRI): a retrospective comparison in 66 breast lesions. Diagn Interv Imaging 98:113–123CrossRef
14.
go back to reference Jochelson MS, Pinker K, Dershaw D et al (2017) Comparison of screening CEDM and MRI for women at increased risk for breast cancer: a pilot study. Eur J Radiol 97:37–43CrossRef Jochelson MS, Pinker K, Dershaw D et al (2017) Comparison of screening CEDM and MRI for women at increased risk for breast cancer: a pilot study. Eur J Radiol 97:37–43CrossRef
15.
go back to reference Sorin V, Yagil Y, Yosepovich A et al (2018) Contrast-enhanced spectral mammography in women with intermediate breast cancer risk and dense breasts. AJR Am J Roentgenol 211:W1–W8CrossRef Sorin V, Yagil Y, Yosepovich A et al (2018) Contrast-enhanced spectral mammography in women with intermediate breast cancer risk and dense breasts. AJR Am J Roentgenol 211:W1–W8CrossRef
16.
go back to reference Jeukens CR, Lalji UC, Meijer E et al (2014) Radiation exposure of contrast-enhanced spectral mammography compared with full-field digital mammography. Invest Radiol 49:659–665CrossRef Jeukens CR, Lalji UC, Meijer E et al (2014) Radiation exposure of contrast-enhanced spectral mammography compared with full-field digital mammography. Invest Radiol 49:659–665CrossRef
17.
go back to reference Lalji UC, Houben IP, Prevos R et al (2016) Contrast-enhanced spectral mammography in recalls from the Dutch breast cancer screening program: validation of results in a larger multireader, multicase study. Eur Radiol 26:4371–4379CrossRef Lalji UC, Houben IP, Prevos R et al (2016) Contrast-enhanced spectral mammography in recalls from the Dutch breast cancer screening program: validation of results in a larger multireader, multicase study. Eur Radiol 26:4371–4379CrossRef
18.
go back to reference Tango T (1998) Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med 17:891–908CrossRef Tango T (1998) Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med 17:891–908CrossRef
19.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845CrossRef DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845CrossRef
21.
go back to reference McDonald RJ, McDonald JS, Kallmes DF et al (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275:772–782CrossRef McDonald RJ, McDonald JS, Kallmes DF et al (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275:772–782CrossRef
22.
go back to reference McDonald RJ, McDonald JS, Kallmes DF et al (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 285:546–554CrossRef McDonald RJ, McDonald JS, Kallmes DF et al (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 285:546–554CrossRef
23.
go back to reference Patel BK, Lobbes MBI, Lewin J (2018) Contrast enhanced spectral mammography: a review. Semin Ultrasound CT MR 39:70–79CrossRef Patel BK, Lobbes MBI, Lewin J (2018) Contrast enhanced spectral mammography: a review. Semin Ultrasound CT MR 39:70–79CrossRef
24.
go back to reference Lobbes MB, Lalji UC, Nelemans PJ et al (2015) The quality of tumor size assessment by contrast-enhanced spectral mammography and the benefit of additional breast MRI. J Cancer 6:144–150CrossRef Lobbes MB, Lalji UC, Nelemans PJ et al (2015) The quality of tumor size assessment by contrast-enhanced spectral mammography and the benefit of additional breast MRI. J Cancer 6:144–150CrossRef
25.
go back to reference National Research Council (2006) Health risks for exposure to low levels of ionizing radiation: BEIR VII phase, 2nd edn. National Academic Press, Washington, DC National Research Council (2006) Health risks for exposure to low levels of ionizing radiation: BEIR VII phase, 2nd edn. National Academic Press, Washington, DC
26.
go back to reference Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG (2012) Reporting of non-inferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 308:2594–2604 Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG (2012) Reporting of non-inferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 308:2594–2604
27.
go back to reference Van Nijnatten TJA, Jochelson MS, Pinker K, et al (2019) Differences in degree of enhancement on CEM between ILC and IDC. BJR Open 5:20180046 Van Nijnatten TJA, Jochelson MS, Pinker K, et al (2019) Differences in degree of enhancement on CEM between ILC and IDC. BJR Open 5:20180046
29.
go back to reference Houben IPL, Van de Voorde P, Jeukens CRLPN et al (2017) Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits. Eur J Radiol 94:31–37CrossRef Houben IPL, Van de Voorde P, Jeukens CRLPN et al (2017) Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits. Eur J Radiol 94:31–37CrossRef
30.
go back to reference Nijssen EC, Rennenberg RJ, Nelemans PJ et al (2017) Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomized, phase 3, controlled, open-label, non-inferiority trial. Lancet 389:1312–1322CrossRef Nijssen EC, Rennenberg RJ, Nelemans PJ et al (2017) Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomized, phase 3, controlled, open-label, non-inferiority trial. Lancet 389:1312–1322CrossRef
31.
go back to reference Checka CM, Chun JE, Schnabel FR, Lee J, Toth H (2012) The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol 198:W292–W295CrossRef Checka CM, Chun JE, Schnabel FR, Lee J, Toth H (2012) The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol 198:W292–W295CrossRef
32.
go back to reference Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ (2017) Association of BRCA mutation types, imaging features, and pathologic findings in patients with breast cancer with BRCA1 and BRCA2 mutations. AJR Am J Roentgenol 209:920–928 Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ (2017) Association of BRCA mutation types, imaging features, and pathologic findings in patients with breast cancer with BRCA1 and BRCA2 mutations. AJR Am J Roentgenol 209:920–928
33.
go back to reference Lord SJ, Lei W, Craft P et al (2007) A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 43:1905–1917CrossRef Lord SJ, Lei W, Craft P et al (2007) A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 43:1905–1917CrossRef
Metadata
Title
Evaluation of single-view contrast-enhanced mammography as novel reading strategy: a non-inferiority feasibility study
Authors
M. B. I. Lobbes
J. Hecker
I. P. L. Houben
R. Pluymakers
C. Jeukens
U. C. Laji
S. Gommers
J. E. Wildberger
P. J. Nelemans
Publication date
01-11-2019
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 11/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-019-06215-7

Other articles of this Issue 11/2019

European Radiology 11/2019 Go to the issue